Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Division of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Davis, CA.
Chest. 2022 Aug;162(2):394-405. doi: 10.1016/j.chest.2022.03.023. Epub 2022 Mar 23.
Patients with familial pulmonary fibrosis represent a subset of patients with pulmonary fibrosis in whom inherited gene variation predisposes them to disease development. In the appropriate setting, genetic testing allows for personalized assessment of disease, recognition of clinically relevant extrapulmonary manifestations, and assessing susceptibility in unaffected relatives. However currently, the use of genetic testing is inconsistent, partly because of the lack of guidance regarding high-yield scenarios in which the results of genetic testing can inform clinical decision-making. To address this, the Pulmonary Fibrosis Foundation commissioned a genetic testing work group comprising pulmonologists, geneticists, and genetic counselors from the United States to provide guidance on genetic testing in patients with pulmonary fibrosis. This CHEST special feature presents a concise review of these proceedings and reviews pulmonary fibrosis susceptibility, clinically available genetic testing methods, and clinical scenarios in which genetic testing should be considered.
特发性肺纤维化患者代表了肺纤维化患者中的一个亚组,其遗传基因变异使他们易患疾病。在适当的情况下,基因检测可用于对疾病进行个体化评估,识别临床相关的肺外表现,并评估未受影响亲属的易感性。然而,目前基因检测的使用并不一致,部分原因是缺乏关于高收益场景的指导,在这些场景中,基因检测结果可以为临床决策提供信息。为了解决这个问题,美国的肺纤维化基金会委托一个由肺科医生、遗传学家和遗传咨询师组成的基因检测工作组,就肺纤维化患者的基因检测提供指导。本《 CHEST 特刊》简要介绍了这些程序,并回顾了肺纤维化易感性、临床可用的基因检测方法以及应考虑进行基因检测的临床情况。